1199 Determining the Underlying Mechanisms of Glioma Progression and Recurrence

View at publisher Summarise with VIRAT
Authors: Mathew Ryan Voisin, Alexander Landry, Jeff Liu, Julio Sosa, Shahbaz Khan, Olivia Singh, Sheila Mansouri, Jeffrey Zuccato, Qingxia Wei, Andrew F. Gao, Thomas Kislinger, Vikas Patil
+1 more Gelareh Zadeh
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Despite recent advances in the molecular characterization of gliomas, there remains a need to better understand tumor progression through biomarkers and predictors of recurrence that can be leveraged as potential future therapeutic targets. METHODS: We generated a cohort of 271 gliomas from 176 patients including a unique cohort of 81 patients with paired primary (pre-treatment) and recurrent (post-treatment) tumors using a comprehensive integrated multi-platform analysis consisting of DNA methylation, proteomics, and gene expression data, with 10-year follow-up data. RESULTS: Recurrent IDH mutant gliomas exhibited a global loss of methylation at recurrence, specifically those that undergo malignant transformation to higher grade tumors at recurrence. The transcription family ATF is associated with malignant transformation, and NFATC1 is a biomarker of poor prognosis. Both PABN1L and NOTUM are plasma biomarkers of progression that can be measured longitudinally to monitor risk of recurrence and progression non-invasively. In IDH wildtype GBM, we identified and characterized a novel subgroup associated with longer survival, decreased immune and mesenchymal infiltration, and global increase in methylation. We identified and validated two novel biomarkers, PDE9A and RASA4, associated with this subgroup and prolonged survival. CONCLUSIONS: In summary, we have defined a comprehensive, multi-platform analysis of paired gliomas that has led to the identification of novel subgroups of recurrent disease, new clinically applicable biomarkers for disease progression, and a resource for future studies.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Acute Myeloid Leukemia Research Cancer Genomics and Diagnostics

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
234–234
Publication date
26 March 2026
Language
EN